| P50 | author | Rosario Yerbes | Q39031881 |
| | Abelardo López-Rivas | Q39031948 |
| | Adriana Eramo | Q39906067 |
| | Ruggero De Maria | Q64679020 |
| P2093 | author name string | Gustavo Ortiz-Ferrón | |
| | Ana I López-Pérez | |
| P2860 | cites work | Inhibition of death receptor signals by cellular FLIP | Q24316446 |
| | Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members | Q24337108 |
| | Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL | Q24554360 |
| | Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts | Q24793079 |
| | Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol | Q24805832 |
| | Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli | Q28116145 |
| | TRAIL receptor-2 signals apoptosis through FADD and caspase-8 | Q28142998 |
| | Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex | Q28209029 |
| | Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors | Q28245164 |
| | Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1 | Q28256819 |
| | Death receptors: signaling and modulation | Q28280897 |
| | FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2 | Q28609079 |
| | Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy | Q30586812 |
| | Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5. | Q31120918 |
| | Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 |
| | Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo | Q34082542 |
| | Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. | Q34438239 |
| | Potential and caveats of TRAIL in cancer therapy | Q34625563 |
| | Cyclin-dependent kinase inhibitors | Q35193645 |
| | Promoting apoptosis as a strategy for cancer drug discovery | Q36292878 |
| | Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms | Q36529789 |
| | E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis | Q36565534 |
| | An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis | Q38290395 |
| | Direct repression of the Mcl-1 promoter by E2F1. | Q38291801 |
| | NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling | Q39459534 |
| | c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis | Q39644966 |
| | Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation | Q39895438 |
| | Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. | Q40227228 |
| | Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells | Q40236310 |
| | Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis | Q40316401 |
| | Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. | Q40384718 |
| | E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short). | Q40391790 |
| | Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells | Q40414448 |
| | Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail | Q40424237 |
| | Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. | Q40448034 |
| | Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. | Q40479108 |
| | Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells | Q40504942 |
| | Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. | Q40554408 |
| | Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. | Q40560316 |
| | Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. | Q40599197 |
| | Myeloid cell factor-1 is a critical survival factor for multiple myeloma | Q40655990 |
| | Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing | Q40674172 |
| | Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases | Q40791420 |
| | Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development | Q40868554 |
| | Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines | Q40871201 |
| | Role of acidic sphingomyelinase in Fas/CD95-mediated cell death. | Q41725574 |
| | Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. | Q41747264 |
| | Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. | Q42099676 |
| | The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway | Q42832237 |
| | Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells | Q43722451 |
| | Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. | Q44165080 |
| | Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway | Q44389071 |
| | Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling | Q44550507 |
| | Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation | Q44905141 |
| | A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. | Q45251395 |
| | Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts | Q46383982 |
| | Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. | Q48965240 |
| | Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. | Q51028667 |
| | MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. | Q53398443 |
| | The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels. | Q53988288 |
| | In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) | Q78516462 |
| | Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis | Q82096730 |
| | TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma | Q83919556 |
| P433 | issue | 6 | |
| P921 | main subject | pleiotropy | Q1134884 |
| | apoptotic process | Q14599311 |
| P304 | page(s) | 664-676 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Cell Research | Q1524018 |
| P1476 | title | Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism | |
| P478 | volume | 18 | |